The 2022 hormone therapy position statement of The North American Menopause Society

ObjectiveThis position statement aimed to update the evidence-based position statement published by The North American Menopause Society (NAMS) in 2010 regarding recommendations for hormone therapy (HT) for postmenopausal women. This updated position statement further distinguishes the emerging differences in the therapeutic benefit-risk ratio between estrogen therapy (ET) and combined estrogen-progestogen therapy (EPT) at various ages and time intervals since menopause onset. MethodsAn Advisory Panel of expert clinicians and researchers in the field of women’s health was enlisted to review the 2010 NAMS position statement, evaluate new evidence, and reach consensus on recommendations. The Panel’s recommendations were reviewed and approved by the NAMS Board of Trustees as an official NAMS position statement. ResultsCurrent evidence supports the use of HT for perimenopausal and postmenopausal women when the balance of potential benefits and risks is favorable for the individual woman. This position statement reviews the effects of ET and EPT on many aspects of women’s health and recognizes the greater safety profile associated with ET. ConclusionsRecent data support the initiation of HT around the time of menopause to treat menopause-related symptoms and to prevent osteoporosis in women at high risk of fracture. The more favorable benefit-risk ratio for ET allows more flexibility in extending the duration of use compared with EPT, where the earlier appearance of increased breast cancer risk precludes a recommendation for use beyond 3 to 5 years.

[1]  A. LaCroix,et al.  Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. , 2005, Archives of internal medicine.

[2]  Francine Grodstein,et al.  The incidence of urinary incontinence across Asian, black, and white women in the United States. , 2010, American journal of obstetrics and gynecology.

[3]  D. Mishell,et al.  Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder , 2011, Menopause.

[4]  S. E. Dietert,et al.  Noncontraceptive estrogen use and the occurrence of ovarian cancer. , 1982, Journal of the National Cancer Institute.

[5]  N. Avis,et al.  Endocrine aspects of women's sexual function. , 2010, The journal of sexual medicine.

[6]  H. Arnesen,et al.  Increased Risk of Recurrent Venous Thromboembolism during Hormone Replacement Therapy , 2000, Thrombosis and Haemostasis.

[7]  C. Viscoli,et al.  A clinical trial of estrogen-replacement therapy after ischemic stroke. , 2001, The New England journal of medicine.

[8]  D. Cramer,et al.  Oral medroxyprogesterone in the treatment of postmenopausal symptoms. , 1980, JAMA.

[9]  E. Barrett-Connor,et al.  Hormone replacement therapy, heart disease, and other considerations. , 1998, Annual review of public health.

[10]  M. Beckmann,et al.  Hormone Replacement Therapy after Treatment of Breast Cancer: Effects on Postmenopausal Symptoms, Bone Mineral Density and Recurrence Rates , 2001, Oncology.

[11]  A. Folsom,et al.  Estrogen Replacement Therapy and Ovarian Cancer , 2004, Epidemiology.

[12]  E. Barrett-Connor,et al.  Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. , 2002, The American journal of medicine.

[13]  L. Giudice.  Clinical practice. Endometriosis. , 2010, The New England journal of medicine.

[14]  P. Hartge,et al.  Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. , 2006, Journal of the National Cancer Institute.

[15]  D. White,et al.  Increased estradiol and improved sleep, but not hot flashes, predict enhanced mood during the menopausal transition. , 2011, The Journal of clinical endocrinology and metabolism.

[16]  M. Espeland,et al.  Effect of Postmenopausal Hormone Therapy on Glucose and Insulin Concentrations , 1998, Diabetes Care.

[17]  Teresa Seeman,et al.  Menopause-associated symptoms and cognitive performance: results from the study of women's health across the nation. , 2010, American journal of epidemiology.

[18]  J. Manson,et al.  Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. , 2011, Archives of internal medicine.

[19]  Lewis H Kuller,et al.  Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. , 2009, American journal of epidemiology.

[20]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[21]  R. Chlebowski,et al.  Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence , 2005, Breast Cancer Research.

[22]  Bin Wang,et al.  Hormone replacement therapy and ovarian cancer risk: a meta-analysis. , 2008, Gynecologic oncology.

[23]  Lewis H Kuller,et al.  Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. , 2008, American journal of epidemiology.

[24]  J. Gallagher,et al.  Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization , 2011, Menopause.

[25]  J. Ockene,et al.  Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial , 2010, Menopause.

[26]  E. Vittinghoff,et al.  Postmenopausal Hormones and Incontinence: The Heart and Estrogen/Progestin Replacement Study , 2001, Obstetrics and Gynecology.

[27]  C. Loprinzi,et al.  International Journal of Women's Health Dovepress Management of Menopause-associated Vasomotor Symptoms: Current Treatment Options, Challenges and Future Directions , 2022 .

[28]  K. Yaffe,et al.  Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. , 1998, JAMA.

[29]  S. Davis,et al.  Endocrine aspects of female sexual dysfunction. , 2004, The journal of sexual medicine.

[30]  B. Sherwin,et al.  Effects of estrogen on memory function in surgically menopausal women , 1992, Psychoneuroendocrinology.

[31]  N. Panay,et al.  Recommendations for the management of postmenopausal vaginal atrophy , 2010, Climacteric : the journal of the International Menopause Society.

[32]  G. Bachmann,et al.  Lowest Effective Transdermal 17β-Estradiol Dose for Relief of Hot Flushes in Postmenopausal Women: A Randomized Controlled Trial , 2007, Obstetrics and gynecology.

[33]  J. Manson,et al.  Hormone therapy and physical function change among older women in the Women's Health Initiative: a randomized controlled trial , 2010, Menopause.

[34]  M. Thun,et al.  Postmenopausal Hormone Therapy and Lung Cancer Risk in the Cancer Prevention Study II Nutrition Cohort , 2008, Cancer Epidemiology Biomarkers & Prevention.

[35]  E. Wynder,et al.  Re: Endocrine factors and adenocarcinoma of the lung in women. , 1994, Journal of the National Cancer Institute.

[36]  C. Efthymiou.  Endometriosis-associated intestinal tumours: a consequence of long-term unopposed oestrogen? , 2009, Annals of the Royal College of Surgeons of England.

[37]  W. Stamm,et al.  A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. , 1993, The New England journal of medicine.

[38]  E. Barrett-Connor,et al.  Coronary heart disease in women, randomized clinical trials, HERS and RUTH. , 1998, Maturitas.

[39]  K. Kerlikowske,et al.  Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.

[40]  D. Becker,et al.  Ageing, menopause, and ischaemic heart disease mortality in England, Wales, and the United States: modelling study of national mortality data , 2011, BMJ : British Medical Journal.

[41]  S. Bebar,et al.  A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[42]  E. Vittinghoff,et al.  Factor V Leiden, Hormone Replacement Therapy, and Risk of Venous Thromboembolic Events in Women With Coronary Disease , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[43]  R. Haimov-Kochman,et al.  Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. , 2006, Menopause.

[44]  Garnet L Anderson,et al.  Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. , 2006, JAMA.

[45]  J. Manson,et al.  Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial , 2009, The Lancet.

[46]  R. Karas,et al.  Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. , 2006, Journal of the American College of Cardiology.

[47]  Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. , 2008, JAMA.

[48]  B. Howard,et al.  Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial , 2004, Diabetologia.

[49]  S. Cummings,et al.  Hormone therapy to prevent disease and prolong life in postmenopausal women , 1992, Annals of internal medicine.

[50]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[51]  E. Pukkala,et al.  Endometrial Cancer in Postmenopausal Women Using Estradiol–Progestin Therapy , 2009, Obstetrics and gynecology.

[52]  E. Oger,et al.  Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk , 2003, The Lancet.

[53]  S. Crawford,et al.  Factors associated with age at natural menopause in a multiethnic sample of midlife women. , 2001, American journal of epidemiology.

[54]  M. Alhenc-Gelas,et al.  Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen , 2010, Menopause.

[55]  V. Henderson.  Gonadal Hormones and Cognitive Aging: A Midlife Perspective , 2011, Women's health.

[56]  F. Stanczyk,et al.  Misconception and concerns about bioidentical hormones used for custom-compounded hormone therapy. , 2012, The Journal of clinical endocrinology and metabolism.

[57]  E. Salpeter,et al.  Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. , 2009, The American journal of medicine.

[58]  L. Peltonen,et al.  Parkinsonism, premature menopause, and mitochondrial DNA polymerase γ mutations: clinical and molecular genetic study , 2004, The Lancet.

[59]  F. Speizer,et al.  A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease , 2000, Annals of Internal Medicine.

[60]  D. Herrington,et al.  The Heart and Estrogen/Progestin Replacement Study , 1999, Drugs & aging.

[61]  R. Lobo.  The risk of stroke in postmenopausal women receiving hormonal therapy , 2009, Climacteric : the journal of the International Menopause Society.

[62]  J. Cauley,et al.  Menopausal Symptoms in Older Women and the Effects of Treatment With Hormone Therapy , 2002, Obstetrics and gynecology.

[63]  H. Wichmann,et al.  Hormonal factors and risk of lung cancer among women? , 2003, International journal of epidemiology.

[64]  E. Vittinghoff,et al.  Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial , 2003, Annals of Internal Medicine.

[65]  B. Eriksen.  A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. , 1999, American journal of obstetrics and gynecology.

[66]  P. Scarabin,et al.  Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. , 2011, Maturitas.

[67]  A. Schwartz,et al.  Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  J. Dungan.  Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin , 2009 .

[69]  J. Manson,et al.  Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. , 2010, Journal of the National Cancer Institute.

[70]  D. Rubinow,et al.  Estrogen replacement in perimenopause-related depression: a preliminary report. , 2000, American journal of obstetrics and gynecology.

[71]  Susan R. Johnson,et al.  Menopausal Symptoms and Treatment-Related Effects of Estrogen and Progestin in the Women's Health Initiative , 2005, Obstetrics and gynecology.

[72]  P. Hannaford,et al.  Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. , 2006, Contraception.

[73]  F. Grodstein,et al.  Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women , 2004, Neurology.

[74]  Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy: A Randomized Controlled Trial , 2011 .

[75]  S. Soontrapa,et al.  Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis , 2011, Menopause.

[76]  G. Bachmann,et al.  Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. , 2001, Fertility and sterility.

[77]  J. Manson,et al.  Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative , 2011, Menopause.

[78]  J. Manson,et al.  Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. , 2010, JAMA.

[79]  L. Melton,et al.  Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause , 2007, Neurology.

[80]  I. Katz,et al.  Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial , 2004, Biological Psychiatry.

[81]  Y. Street.  The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women , 2006 .

[82]  J. Manson,et al.  Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. , 2008, Archives of internal medicine.

[83]  Heart disease risk determines menopausal age rather than the reverse. , 2006, Journal of the American College of Cardiology.

[84]  S. Cummings,et al.  Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial , 2004, Obstetrics and gynecology.

[85]  M. Otto,et al.  Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. , 2006, Archives of general psychiatry.

[86]  B. Whitcomb,et al.  The association of hormone replacement therapy and coronary calcium as determined by electron beam tomography. , 2002, Journal of women's health & gender-based medicine.

[87]  M. Tattersall,et al.  Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality , 2003, The Medical journal of Australia.

[88]  Ross L Prentice,et al.  Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. , 2005, American journal of epidemiology.

[89]  P. Hietanen,et al.  A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy. , 2001, Maturitas.

[90]  N. Hacker,et al.  Hormone replacement therapy and risk of epithelial ovarian cancer , 1999, British Journal of Cancer.

[91]  Lin Shou-qin,et al.  The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women:2007 position statement of The North American Menopause Society , 2008 .

[92]  J. Manson,et al.  Estrogen therapy and coronary-artery calcification. , 2007, The New England journal of medicine.

[93]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[94]  L. Ford,et al.  Paradoxical Clinical Effect of Estrogen on Breast Cancer Risk: A “New” Biology of Estrogen-induced Apoptosis , 2011, Cancer Prevention Research.

[95]  M. Thun,et al.  Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. , 2001, JAMA.

[96]  E. Vittinghoff,et al.  The Effect of Ultralow-Dose Transdermal Estradiol on Urinary Incontinence in Postmenopausal Women , 2005, Obstetrics and gynecology.

[97]  S. Shapiro,et al.  Noncontraceptive estrogen use and epithelial ovarian cancer. , 1989, American journal of epidemiology.

[98]  H. Olsson,et al.  Are Smoking‐Associated Cancers Prevented or Postponed in Women Using Hormone Replacement Therapy? , 2003, Obstetrics and gynecology.

[99]  G A Colditz,et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.

[100]  J. Manson,et al.  Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses’ Health Study , 2009, Obstetrics and gynecology.

[101]  S. Suissa,et al.  Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study , 2010, BMJ : British Medical Journal.

[102]  M. Inoue,et al.  Reproductive factors, hormone use and the risk of lung cancer among middle‐aged never‐smoking Japanese women: A large‐scale population‐based cohort study , 2005, International journal of cancer.

[103]  J. Weissfeld,et al.  Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. , 2002, Gynecologic oncology.

[104]  P. Scarabin.  Hormone therapy and venous thromboembolism among postmenopausal women. , 2014, Frontiers of hormone research.

[105]  S. Störk,et al.  Effect of Oral Postmenopausal Hormone Replacement on Progression of Atherosclerosis: A Randomized, Controlled Trial , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[106]  A. Maclennan,et al.  Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. , 2004, The Cochrane database of systematic reviews.

[107]  D. B. Williams,et al.  Effects of hormone replacement therapy on cognitive performance in elderly women. , 2001, Maturitas.

[108]  L. Kestin,et al.  Estrogen replacement therapy in breast cancer survivors: a matched-controlled series , 2003, Menopause.

[109]  K. Matthews,et al.  Prior to use of estrogen replacement therapy, are users healthier than nonusers? , 1996, American journal of epidemiology.

[110]  S. Resnick,et al.  0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(5):1802–1810 Printed in U.S.A. Copyright © 2006 by The Endocrine Society doi: 10.1210/jc.2005-2097 Effects of Combination Estrogen Plus Progestin Hormone Treatment on Cognition an , 2022 .

[111]  J. Cauley,et al.  Surgical menopause and nonvertebral fracture risk among older US women , 2012, Menopause.

[112]  Anthony Dowell,et al.  Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women , 2007, BMJ : British Medical Journal.

[113]  S. Azen,et al.  Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. , 2001, Annals of internal medicine.

[114]  E. Greiser,et al.  Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. , 2007, Human reproduction update.

[115]  F. Clavel-Chapelon,et al.  Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  S. Rich,et al.  Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. , 2003, The Journal of clinical endocrinology and metabolism.

[117]  L. Lisabeth,et al.  Stroke risk in women: the role of menopause and hormone therapy , 2012, The Lancet Neurology.

[118]  Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study , 2007, Circulation.

[119]  R. Jacobsen,et al.  Hormone therapy and risk of myocardial infarction: a national register study. , 2008, European heart journal.

[120]  E. Løkkegaard,et al.  Hormone therapy and ovarian cancer. , 2009, JAMA.

[121]  J. Manson,et al.  Symptom experience after discontinuing use of estrogen plus progestin. , 2005, JAMA.

[122]  M. Spitz,et al.  Hormone Replacement Therapy and Lung Cancer Risk , 2004, Clinical Cancer Research.

[123]  B. Sherwin,et al.  Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women , 1988, Psychoneuroendocrinology.

[124]  E. Greiser,et al.  Menopausal hormone therapy and risk of lung cancer-Systematic review and meta-analysis. , 2010, Maturitas.

[125]  N. Natarajan,et al.  Hormone Replacement Therapy as a Risk Factor for Non-Small Cell Lung Cancer: Results of a Case-Control Study , 2008, Oncology.

[126]  Ruth Rojahn.  Oestrogen therapy for urinary incontinence in post-menopausal women. , 2011 .

[127]  J. Dungan.  Ovarian Conservation at the Time of Hysterectomy and Long-Term Health Outcomes in the Nurses' Health Study , 2010 .

[128]  V. Henderson,et al.  Surgical versus natural menopause: cognitive issues , 2007, Menopause.

[129]  R. Langer,et al.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. , 2003, JAMA.

[130]  E. Salpeter,et al.  Brief report: Coronary heart disease events associated with hormone therapy in younger and older women , 2006, Journal of General Internal Medicine.

[131]  Mary Cushman,et al.  Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.

[132]  B. Thomsen,et al.  Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. , 2004, Archives of internal medicine.

[133]  H. Risch.  Estrogen replacement therapy and risk of epithelial ovarian cancer. , 1996, Gynecologic oncology.

[134]  L. Altshuler,et al.  Estrogen and response to sertraline in postmenopausal women with major depressive disorder: a pilot study. , 2007, Journal of psychiatric research.

[135]  Menopausal hormone replacement therapy and risk of ovarian cancer , 2002, JAMA.

[136]  N. Weiss,et al.  Menopausal Hormone Therapy and Risk of Epithelial Ovarian Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[137]  Susan R. Johnson,et al.  Uterine and Vaginal Effects of Unopposed Ultralow-Dose Transdermal Estradiol , 2005, Obstetrics and gynecology.

[138]  A. LaCroix,et al.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.

[139]  Ana Maria Lopez,et al.  Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. , 2003, JAMA.

[140]  A. Ziogas,et al.  Breast Cancer Survival and Hormone Replacement Therapy: A Cohort Analysis , 2000, American journal of clinical oncology.

[141]  P. Hannaford,et al.  Use of exogenous hormones by women and colorectal cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. , 2005, Contraception.

[142]  Peter B. Schiff,et al.  Surveillance Epidemiology and End Results (SEER) analysis confirms overall survival benefit with concurrent chemoradiotherapy for cervical cancer , 2013 .

[143]  R. Langer,et al.  Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus , 2006, Archives of internal medicine.

[144]  Charles B Eaton,et al.  Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. , 2006, Archives of internal medicine.

[145]  L. Holmberg,et al.  Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. , 2008, Journal of the National Cancer Institute.

[146]  C. Soares,et al.  Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. , 2001, Archives of general psychiatry.

[147]  T. Bevers,et al.  Breast cancer risk in relation to the interval between menopause and starting hormone therapy: Beral V, for the Million Women Study Collaborators (Univ of Oxford, UK; Et al) J Natl Cancer Inst 103:296-305, 2011 , 2011 .

[148]  G. Colditz,et al.  Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. , 2000, American journal of epidemiology.

[149]  E. Barrett-Connor,et al.  Hormone therapy and coronary artery calcification in asymptomatic postmenopausal women: the Rancho Bernardo Study , 2005, Menopause.

[150]  M. Duh,et al.  Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy , 2011, Menopause.

[151]  G. Bachmann,et al.  The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society , 2007, Menopause.

[152]  S. Resnick,et al.  Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. , 2009, The Journal of clinical endocrinology and metabolism.

[153]  M. Marmot,et al.  Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study , 1997, The Lancet.

[154]  J. Park,et al.  Hormone therapy and risk of lung cancer: a meta-analysis. , 2010, Journal of Women's Health.

[155]  C. Ribot,et al.  Effect of hormone replacement therapy on age-related increase in carotid artery intima-media thickness in postmenopausal women. , 2000, Atherosclerosis.

[156]  A. Berchuck,et al.  Menopausal hormones and risk of ovarian cancer. , 2005, American journal of obstetrics and gynecology.

[157]  V. Beral,et al.  Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy , 2011, Journal of the National Cancer Institute.

[158]  F. Drobniewski,et al.  Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women : systematic review and meta-analysis , 2008 .

[159]  J. Hsia,et al.  Postmenopausal Hormone Therapy and Risk of Stroke: The Heart and Estrogen-progestin Replacement Study (HERS) , 2001, Circulation.

[160]  E. Weiderpass,et al.  Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. , 2002, Journal of the National Cancer Institute.

[161]  J. Manson,et al.  Calcium plus vitamin D supplementation and the risk of fractures. , 2006, The New England journal of medicine.

[162]  E. Vittinghoff,et al.  Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. , 2002, JAMA.

[163]  R. Prentice,et al.  Estrogen plus progestin and risk of venous thrombosis. , 2004, JAMA.

[164]  E. Barrett-Connor,et al.  Estrogen and coronary heart disease in women , 1991, JAMA.

[165]  L. G. García Rodríguez,et al.  Hormone therapy and cerebrovascular events: a population-based nested case-control study , 2006, Menopause.

[166]  G. Heiss,et al.  The effect of conjugated equine oestrogen on diabetes incidence: the Women’s Health Initiative randomised trial , 2006, Diabetologia.

[167]  E. White,et al.  Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  G. Anderson,et al.  Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. , 2006, Maturitas.

[169]  T. Seeman,et al.  Effects of the menopause transition and hormone use on cognitive performance in midlife women , 2009, Neurology.

[170]  B. Howard,et al.  Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials. , 2010, Archives of internal medicine.

[171]  R. Wallace,et al.  Effects of estrogen with and without progestin on urinary incontinence. , 2005, JAMA.

[172]  C. Kooperberg,et al.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. , 2003, JAMA.

[173]  G. B. Lopes,et al.  Effects of estrogen plus progestin on health-related quality of life. , 2004, The New England journal of medicine.

[174]  J. Manson,et al.  Unopposed estrogen therapy and the risk of invasive breast cancer. , 2006, Archives of internal medicine.

[175]  S. Corson.  Hormone Therapy and Ovarian Cancer By Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, and Lidegaard ØL. JAMA 2009:302:298-305 , 2009 .

[176]  J. Manson,et al.  Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. , 2007, JAMA.